Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BCT197

Other · developed by Mereo BioPharma

Phase 2 Most advanced trial (none active)
MREO Developer
2 Registered trials

What is BCT197?

BCT197 is a drug studied in patients with chronic obstructive pulmonary disease and acute kidney injury.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Renal & urology, Respiratory
Developer
Mereo BioPharma (MREO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01336959 Phase 2 Acute Kidney Injury Terminated MREO
NCT01332097 Phase 2 Chronic Obstructive Pulmonary Disease Completed MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Kidney InjuryChronic Obstructive Pulmonary Disease

More from Mereo BioPharma

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MREO page.

Follow MREO, the company behind BCT197

See MREO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MREO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.